Healthcare [ 3/11 ] | Biotechnology [ 38/157 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Mar 15, 23 | -0.06
Decreased by
-100.00%
|
-0.04
Decreased by
-1.25 K%
|
Dec 12, 22 | -0.03
Increased by
+25.00%
|
-0.04
Increased by
+625.00%
|
Sep 13, 22 | -0.03 | -0.07
Increased by
+816.33%
|
Jul 19, 22 | -0.04 | -0.03
Decreased by
-1.11 K%
|
Mar 15, 22 | -0.03 | -0.03 |
Dec 13, 21 | -0.04 | -0.02
Decreased by
-5.00 K%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Jan 31, 23 | 0.00
Decreased by
N/A%
|
-5.43 M
Decreased by
-110.88%
|
Decreased by
N/A%
Decreased by
N/A%
|
Oct 31, 22 | 0.00
Decreased by
N/A%
|
-3.11 M
Increased by
+13.61%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jul 31, 22 | 0.00
Decreased by
N/A%
|
-3.04 M
Decreased by
-30.92%
|
Decreased by
N/A%
Decreased by
N/A%
|
Apr 30, 22 | 0.00
Decreased by
N/A%
|
-3.87 M
Decreased by
-207.87%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jan 31, 22 | 0.00
Decreased by
N/A%
|
-2.57 M
Decreased by
-129.95%
|
Decreased by
N/A%
Decreased by
N/A%
|
Oct 31, 21 | 0.00
Decreased by
N/A%
|
-3.60 M
Decreased by
-165.85%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jul 31, 21 | 0.00
Decreased by
N/A%
|
-2.32 M
Decreased by
-76.18%
|
Decreased by
N/A%
Decreased by
N/A%
|
Apr 30, 21 | 0.00
Decreased by
N/A%
|
-1.26 M
Decreased by
-0.00%
|
Decreased by
N/A%
Decreased by
N/A%
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.